Xiamen INNOBIOMAX Biotechnology Co., Ltd. (hereinafter referred to as "INNOBIOMAX"), established on May 10, 2021, is a subsidiary of WANTAI BioPharm and the fourth WANTAI-affiliated company in Xiamen. INNOBIOMAX is dedicated to bioactive raw materials. 

INNOBIOMAX originated from the Diagnostic R&D Department of Xiamen WANTAI group, which was founded in 2010. Leveraging the Industry-Academia collaboration platform with the NIDVD at Xiamen University, and inheriting the deep expertise of WANTAI and INNODX in the IVD field, INNOBIOMAX has undergone over decades of independent R&D and innovation. Our platforms combine E. coli, CHO, HEK293, and insect cell expression systems with multi-species antibody screening, enabling full-matrix development and high-throughput screening. Our 300+ high-performance raw materials are compatible with POCT FIA, RDT, ELISA, CLIA, and PCR diagnostics, as well as third-party controls and serum panels. 

Moving forward, INNOBIOMAX is working hand-in-hand with global IVD manufacturers to strengthen the bedrock of IVD and public health with world-class raw materials!